654 related articles for article (PubMed ID: 8960666)
21. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
[TBL] [Abstract][Full Text] [Related]
22. Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor.
Harper JL; Gill JC; Hopp RJ; Evans J; Haire WD
Thromb Haemost; 1995 Oct; 74(4):1039-41. PubMed ID: 8560409
[TBL] [Abstract][Full Text] [Related]
23. [Hemophilia A with factor VIII inhibitor].
Shima M
Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
[No Abstract] [Full Text] [Related]
24. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors in mild/moderate haemophilia A: an update.
Franchini M; Salvagno GL; Lippi G
Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
[TBL] [Abstract][Full Text] [Related]
26. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
[TBL] [Abstract][Full Text] [Related]
27. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
DiMichele D; Kroner B;
Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
[TBL] [Abstract][Full Text] [Related]
28. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
29. [Continuous infusion of coagulant factor concentrates and its pharmacokinetics in patients with hemophilics having low titer inhibitor].
Fujii T; Takata N; Kimura A
Rinsho Ketsueki; 2007 Apr; 48(4):321-5. PubMed ID: 17515124
[TBL] [Abstract][Full Text] [Related]
30. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
Buchanan GR; Kevy SV
Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
[TBL] [Abstract][Full Text] [Related]
31. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
32. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
Diniz MJ; Dias Francisco F; Tavares ML; Leal I
Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
[TBL] [Abstract][Full Text] [Related]
33. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
34. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experience--1978-1982.
Eyster ME; Spero JA; Catalano PM; Gill FM; Lusch CJ; Kajani MK; Barron LE; DeGreen HP; Shapiro SS; Lewis JH
Prog Clin Biol Res; 1984; 150():309-22. PubMed ID: 6431435
[TBL] [Abstract][Full Text] [Related]
35. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
Klukowska A; Zieleniewska B
Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
[TBL] [Abstract][Full Text] [Related]
36. Treatment of inhibitor patients with activated prothrombin complex concentrates.
Penner JA
Prog Clin Biol Res; 1984; 150():291-308. PubMed ID: 6431434
[TBL] [Abstract][Full Text] [Related]
37. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the bleeding inhibitor patient.
Astermark J
Semin Thromb Hemost; 2003 Feb; 29(1):77-86. PubMed ID: 12640569
[TBL] [Abstract][Full Text] [Related]
39. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
40. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
Lin PC; Liao YM; Tsai SP; Chang TT
Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
